Summary
The effects of cefodizime (CDZ) on non-specific immunity in patients with multiple myeloma were studied in a randomized, placebo-controlled trial. A total of 51 patients with newly diagnosed multiple myeloma were admitted to the study, 27 of whom received CDZ 2 g i.v. once daily for seven days and 24 ascorbic acid 1 g daily i.v. for one week. Granulocyte chemotaxis, neutrophil biochemiluminescence and phagocytosis were determined at baseline and at 48 h after the last dose. At baseline, chemiluminescence, phagocytosis and, to a lesser extent, granulocyte chemotaxis were diminished in both patient groups compared to healthy volunteers. After treatment, a significant increase in chemiluminescence and phagocytosis was observed in the CDZ group, while a slight increase in granulocyte chemotaxis did not reach statistical significance. No changes were observed in the control group. It is concluded that CDZ enhanced non-specific immune mechanisms in patients with multiple myeloma.
Zusammenfassung
In einer randomisierten Plazebo-kontrollierten Vergleichsstudie wurden die Wirkungen von Cefodizim (CDZ) auf unspezifische Immunfunktionen von Patienten mit multiplem Myelom untersucht. 51 Patienten mit neu diagnostiziertem multiplen Myelom wurden in die Studie aufgenommen, 27 wurden mit CDZ 2 g i.v. einmal täglich über einen Zeitraum von sieben Tagen behandelt, 24 erhielten 1 g/d Ascorbinsäure als i.v. Injektion über sieben Tage. Vor Behandlungsbeginn und 48 Stunden nach der letzten Dosis wurden Chemotaxis und Bio-Chemilumineszenz von neutrophilen Granulozyten sowie die Phagozytose bestimmt. Im Vergleich zu gesunden Probanden waren Chemilumineszenz, Phagozytose und, in geringerem Ausmaß, auch Chemotaxis vermindert. In der CDZ-Gruppe wurden ein signifikanter Anstieg der Chemilumineszenz und der Phagozytose beobachtet, eine geringe Zunahme der Chemotaxis erreichte nicht die Signifikanzschwelle. In der Kontrollgruppe kam es zu keinen signifikanten Veränderungen. Es wird geschlossen, daß Cefodizim bei Patienten mit multiplem Myelom unspezifische Immunmechanismen verstärkt.
Similar content being viewed by others
References
Stjernholm, R. L., Allen, R. C., Steele, R. H., Fahey, J. L. Impaired chemiluminescence during phagocytosis of bacteria. Infect. Immun. 7 (1973) 313–314.
Rosen, H., Klebanoff, S. F. Chemiluminescence and superoxide production by myeloperoxidae-deficient leukocytes. J. Clin. Invest. 58 (1976) 50–60.
Ritchey, E. E., Wallin, D. W., Shah, S. V. Chemiluminescence and superoxide anion production by leukocytes from chronic hemodialysis patients. Kidney Int. 19 (1981) 349–358.
Shah, S., Wallin, J., Cruz, F.: Chemiluminescence and superoxide production by leukocytes from renal transplant patients. Third International Conference on Superoxide and Superoxide Dismutase. New York, NY, 1982, p. 74 (Abstract 117).
Shah, S., Wallin, J. D., Ellen, S. D. Chemiluminescence and superoxide anion production by leukocytes from diabetic patients. J. Clin. Endocrinol. 57 (1983) 402–409.
Lane, H. C., Fauci, A. S. Immunologic abnormalities in the acquired immunodeficiency syndrome. Ann. Rev. Immunol. 3 (1985) 479–489.
Dammacco, F., Miglietta, A., Perfetto, S. C. Impaired chemiluminescence response by neutrophils in patients with multiple myeloma. Scand. J. Haematol. 37 (1986) 289–295.
Dammacco, F., Miglietta, A., Ventura, M. T., Bonomo, L. Defective chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammopathy. Clin. Exp. Immunol. 47 (1982) 481–486.
Ozer, H., Han, T., Henderson, E. S., Nussbaum, A., Sheedy, D. Immunoregulatory T cell function in multiple myeloma. J. Clin. Invest. 67 (1981) 779–789.
Pruzansky, W., Gidon, M. S., Roy, A. Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. Clin. Immunol. Immunopathol. 17 (1980) 280–286.
Miller, T. E., North, D. K. Clinical infections, antibiotics and immunosuppression: a puzzling relationship. Am. J. Med. 71 (1981) 334–336.
Miyake, Y., Tomonaga, M., Tokoh, T., Yamada, Y., Ishida, N., Hyodo, A., Inoue, M., Mitsuhashi, S. Therapeutic efficacy against experimental infections in immunosuppressed mice. Chemotherapy 36 (S-5) (1988) 128–139.
Vanholder, R., Van Landschoot, N., Dagrosa, E., Ringoir, S. Cefodizime: a new cephalosporin with apparent immune-stimulating properties in chronic renal failure. Nephrol. Dial. Transplant. 2 (1988) 221–224.
Carandente, F., De Vecchi, A., Halberg, F., Cornelissen, G., Dammacco, F. Toward a chronoimmunomodulation by cefodizime in multiple myeloma and chronic uremia. Chronobiologia 15 (1988) 61–85.
Boyden, S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. J. Exp. Med. 115 (1962) 453–461.
Robinson, J. P., Penny, R. Chemiluminescence response in normal human phagocytes. II. Effects of paraproteins. J. Clin. Lab. Immunol. 7 (1982) 219–221.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dammacco, F., Benvestito, S. Effects of cefodizime on non-specific immune functions in patients with multiple myeloma. Infection 20 (Suppl 1), S64–S66 (1992). https://doi.org/10.1007/BF01709957
Issue Date:
DOI: https://doi.org/10.1007/BF01709957